Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients

References

• Strong M, Rosenfield J. Amyotrophic lateral sclerosis. A review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:136–43.
   PubMed Web of Science ®Google Scholar
• Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 2005;5:77–87.
   PubMed Web of Science ®Google Scholar
• Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci. 2000;180:7–14.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Ince PG. Glutamate excitotoxicity and amyotrophic lateral sclerosis. J Neurol. 1997;244:S3–14.
   PubMed Web of Science ®Google Scholar
• Bolanos JP, Moro MA, Lizasoain I, Almeida A. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications. Adv Drug Deliv Rev. 2009;61:1299–315.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Remarkable increase in cerebrospinal fluid 3–nytrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129–31.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett. 1999;260:204–6.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, . Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064–74.
   PubMed Web of Science ®Google Scholar
• Ilieva EV, Ayala V, Jove M, Dalfó E, Cacabelos D, Povedano M, . Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130:3111–23.
   PubMed Web of Science ®Google Scholar
• Nakagomi S, Barsoum MJ, Bossy-Wetzel E, Sütterlin C, Malhotra V, Lipton SA. A Golgi fragmentation pathway in neurodegeneration. Neurobiol Dis. 2008;29:221–31.
   PubMed Web of Science ®Google Scholar
• Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998;44:696–9.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Kuzuhara S, Kokubo Y. Increased oxidative stress in patients with amyotrophic lateral sclerosis/ Parkinsonism-dementia complex in the Kii peninsula, Japan. Mov Disord. 2009;24:123–6.
   PubMedGoogle Scholar
• Spasojević I, Stević Z, Nikolić-Kokić A, Jones DR, Blagojević D, Spasić MB. Different roles of radical scavengers: ascorbate and urate in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep. 2010; 15:81–6.
   PubMed Web of Science ®Google Scholar
• Spasojević I, Mojović M, Stević Z, Spasić SD, Jones DR, Morina A, . Bioavailability and catalytic properties of copper and iron for Fenton chemistry in human cerebrospinal fluid. Redox Rep. 2010;15:29–35.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC, editors. Free Radicals in Biology and Medicine. Oxford: Oxford University Press; 2007.
   Google Scholar
• Liu D, Wen J, Liu J, Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999;13:2318–28.
   PubMed Web of Science ®Google Scholar
• Lenter C, editor. Geigy Scientific Tables. Caldwell: West Ciba-Geigy, 1981.
   Google Scholar
• Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, . Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993; 189:843–6.
   PubMed Web of Science ®Google Scholar
• Cheung G, Gawal MJ, Cooper PW, Farb RI, Ang LC, Gawal MJ. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. Radiology. 1995;194: 263–70.
   PubMed Web of Science ®Google Scholar
• Hecht MJ, Fellner F, Fellner C, Hilz MJ, Neundörfer B, Heuss D. Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: a follow-up examination including FLAIR images. J Neurol Sci. 2002;199:59–65.
   PubMed Web of Science ®Google Scholar
• Santillo AF, Skoglund L, Lindau M, Eeg-Olofsson KE, Tovi M, Engler H, . Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Dis Assoc Disord. 2009;23:298–300.
   PubMedGoogle Scholar
• Yasui M, Ota K, Garruto RM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and Parkinsonism-dementia. Neurotoxicology. 1993;14:445–50.
   PubMed Web of Science ®Google Scholar
• Nikolić Kokić A, Stević Z, Stojanović S, Blagojević DP, Jones DR, Pavlović S, . Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep. 2005;10:265–70.
   PubMed Web of Science ®Google Scholar
• Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2009;2:2.
   PubMed Web of Science ®Google Scholar
• Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010;84:825–89.
   PubMed Web of Science ®Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994;124:94–107.
   Google Scholar
• Spasojević I. Free radicals and antioxidants at a glance using EPR spectroscopy. Crit Rev Clin Lab Sci. 2011;48: 114–42.
   PubMed Web of Science ®Google Scholar
• Matías-Guiu J, Galán L, García-Ramos R, Barcia JA, Guerrero A. Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis. Neurología. 2010;25:364–73.
   PubMedGoogle Scholar
• Drechsel H, Jung G. Peptide siderophores. J Pept Sci. 1998;4:147–81.
   PubMedGoogle Scholar
• Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51:333–55.
   PubMed Web of Science ®Google Scholar
• Bonnet AM, Tell G, Schechter PJ, Grove J, Saint-Hilaire MH, de Smet Y, . Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. Mov Disord. 1987;2:117–23.
   PubMedGoogle Scholar
• Mollenhauer B, Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord. 2009;24:1411–26.
   PubMedGoogle Scholar
• Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci. 1998;18:8126–32.
   PubMed Web of Science ®Google Scholar
• Iłzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 2003;107:412–8.
   PubMed Web of Science ®Google Scholar
• Kaufmann E, Boehm BO, Süssmuth SD, Kientsch-Engel R, Sperfeld A, Ludolph AC, . The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2004;371:226–9.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Une F, Utatsu Y, Nomoto M, Furukawa Y, Maruyama Y, . Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Intern Med. 1999;38:133–9.
   PubMedGoogle Scholar
• Museth AK, Brorsson AC, Lundqvist M, Tibell LA, Jonsson BH. The ALS associated mutation G93A in human copper-zinc superoxide dismutation selectively destabilizes the remote metal binding region. Biochemistry. 2009;48: 8817 –29.
   PubMedGoogle Scholar
• Tumani H, Teunissen C, Süssmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diag. 2008;8:479 –94.
   PubMed Web of Science ®Google Scholar
• Ekegren T, Hanrieder J, Bergquist J. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. J Mass Spectrom. 2008;43: 559–71.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, . Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis. 2011; 8:310 –21.
   PubMed Web of Science ®Google Scholar
• Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2009;23:3766–79.
   PubMed Web of Science ®Google Scholar
• Bajić A, Zakrzewska J, Godjevac D, Andjus P, Jones DR, Spasić M, . Relevance of the ability of fructose 1, 6-bis(phosphate) to sequester ferrous but not ferric ions. Carbohydr Res. 2011;346:416–20.
   PubMedGoogle Scholar
• Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr Pharm Des. 2011;17:508–20.
   PubMed Web of Science ®Google Scholar
• Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, . Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457–67.
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011; 118:658–67.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Mikoda N, Kitazawa M, LaFerla FM. Treatment of Alzheimer's disease with anti-homocysteic acid antibody in 3xTg-AD male mice. PLoS One. 2010;5:e8593.
   Google Scholar